Novel Candidate Genes Identified in Men with Congenital Absence of Vas Deferens without CFTR Gene Abnormalities.

The genetic etiology is unknown for 30-40% of men with congenital bilateral absence of the vas deferens (CBAVD) and 70% of those with congenital unilateral absence of the vas deferens (CUAVD). The study aimed to investigate the genetic etiology of CBAVD/CUAVD, both with and without renal anomalies, in individuals who are negative for CFTR pathogenic variants. We included 19 cases of congenital absence of vas deferens (CAVD) that were negative for CFTR variants on Sanger sequencing. Whole-exome sequencing (WES) was performed in 16 men with CAVD. Targeted resequencing was carried out in a total of 19 CAVD cases [16 CAVD cases for which WES was performed and an additional 3 CBAVD cases without renal anomalies]. A novel, hemizygous ADGRG2 pathogenic variant (c.1706 C > T; p.T569I) was identified in two men with CBAVD without renal anomalies. Additionally, we detected pathogenic variants in AR, NCKPAL1, FSHR, and SLC26A4 genes in CBAVD without renal anomalies. Pathogenic variants were detected in FREM1, WNT2B, and TBX6 genes in CBAVD men with renal abnormalities. No variants were detected in CUAVD with renal anomalies. In addition to a novel pathogenic variant in the ADGRG2 gene, we report novel candidate genes AR, NCKPAL1, FSHR, and SLC26A4, for CBAVD. We identified variants in the FREM1, WNT2B, and TBX6 genes in CBAVD with renal anomalies. ADGRG2 testing could be useful for appropriate genetic counselling for the X-linked transmission of the molecular defect in CFTR-negative CBAVD. We recommend whole-exome sequencing for genetic screening of CBAVD for CFTR, ADGRG2, and other candidate genes prior to undergoing Intracytoplasmic sperm injection (ICSI).